<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114197">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766167</url>
  </required_header>
  <id_info>
    <org_study_id>MP-424-K01</org_study_id>
    <nct_id>NCT01766167</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Study of MP-424</brief_title>
  <official_title>Clinical Pharmacology Study of MP-424 in Healthy Male Adult Volunteers (Single- and Multiple-Dose Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct the following evaluations in Korean healthy male adult volunteers receiving a
      single and multiple doses of MP-424 tablets:

        -  Pharmacokinetics of MP-424 after a single and multiple doses.

        -  Safety and tolerability of single and multiple doses of MP-424.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>MP-424 area under the plasma concentration-time curve (AUC) from 0 to infinity in Korean healthy volunteers</measure>
    <time_frame>up to 1 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability in Korean healthy volunteers</measure>
    <time_frame>up to 2 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>MP-424</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-424</intervention_name>
    <description>Low</description>
    <arm_group_label>MP-424</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-424</intervention_name>
    <description>Middle</description>
    <arm_group_label>MP-424</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-424</intervention_name>
    <description>High</description>
    <arm_group_label>MP-424</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-424</intervention_name>
    <description>Multiple</description>
    <arm_group_label>MP-424</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Korean healthy male volunteers aged 20 to 55 years

        Exclusion Criteria:

          -  Subjects with a BMI of &lt;18.5 or &gt;25.0, or body weight of &lt;50kg at prior examination

          -  Subjects who have had surgery that is known to affect gastrointestinal absorption of
             drugs (except for appendectomy and hernia surgery)

          -  Subjects who have had any evidence of cardiac disease at prior examination or who
             have a previous history of cardiac disease

          -  Subjects who are positive for HBs antigen, serologic tests for syphilis, HCV
             antibody, or HIV antibody at prior examination

          -  Subjects who have experienced symptoms of alcohol abuse or excessive alcohol
             ingestion

          -  Subjects who test positive on urinalysis for drug use (amphetamine, benzodiazepine,
             barbiturates, cannabinoid, cocaine, opiates, and methadone) at prior examination

          -  Subjects who do not agree to use a physical contraceptive method during the study
             period

          -  Subjects who do not agree to use contraceptive methods for 90 days after final
             administration of the study drug

          -  Subjects who have consumed grapefruit, Seville orange, star fruit, cranberry, or any
             processed food containing these fruits within 7 days before the commencement of study
             drug administration

          -  Subjects who have consumed health foods containing St John's Wort within 2 weeks
             before study drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuoki Kondo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 2, 2013</lastchanged_date>
  <firstreceived_date>January 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotype 2</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
